Jeong et al. first reported that the combined administration of CBD and oxaliplatin not only inhibited tumor growth, but also induced autophagic death by decreasing phospho-eNOS and SOD2 in oxaliplatin-resistant CRC cells, which suggested that CBD could work as a new therapeutic agent to overcome the chemo-resistance of oxaliplatin in human CRC cells, sparing the neurotoxic side effects of oxaliplatin [77]. Here, NOS3 is linked to colorectal carcinoma.